Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 126

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 126
---
 Tax accounting, (4) amend any material Tax Return in a manner prejudicial to the Company, (5) surrender any claim for a material refund of Taxes, (6) except                 
 in respect of the ongoing audits disclosed in Schedule 18(f) of the Disclosure Letter, settle or compromise any material claim, assessment or other dispute in respect of Taxes, (7) enter into or make any voluntary disclosure with respect to any 
 material amount of Taxes, (8) enter into any Tax sharing, allocation, indemnification, receivable reimbursement, or similar agreement (whether or not written), (9) fail to pay any material Tax as such Tax became due and payable (including any   
 estimated Tax), (10) prepare and file any Tax Return in a manner materially inconsistent with past practice, or (11) incur any material liability for Taxes outside the Discontinuance;                                                              |

| (bb) | except as contemplated in the Agreement, (I) not enter into any transaction or perform any act, and                                                                                                                                             
 (II) use commercially reasonable efforts to not omit any act, in each case, that would reasonably be expected to prevent, be materially inconsistent with, materially delay or otherwise impede the successful completion of the acquisition of 
 Common Shares by the Purchaser pursuant to the Arrangement;                                                                                                                                                                                     |

| (cc) | not enter into any new line of business; |

| (dd) | except in connection with the Distribution, not reduce the stated capital of the securities of the Company or 
 the Subsidiary;                                                                                               |

| (ee) | except in connection with the Distribution, not reduce the paid-up                      
 capital (as defined in the Tax Act) of the securities of the Company or the Subsidiary; |

| (ff) | not disclose any material trade secrets or material confidential information pertaining to the Company or the                                                  
 Subsidiary to any person, other than to persons who are under a contractual, legal, or ethical obligation to maintain the confidentiality of such information; |

| (gg) | not take any action that would, or would reasonably be expected to prevent, materially delay or otherwise        
 impede the consummation of the Arrangement, or the satisfaction of any of the conditions set forth in Article 7; |

| (hh) | enter into or amend any Contract with any broker, finder or investment banker, provided that the foregoing                                                                                                                     
 shall not prohibit the Company from entering into an agreement on commercially reasonable terms with any dealer and proxy solicitation services